SMT202000219T1 - Farmacoforo per l'unduzione di trail - Google Patents

Farmacoforo per l'unduzione di trail

Info

Publication number
SMT202000219T1
SMT202000219T1 SM20200219T SMT202000219T SMT202000219T1 SM T202000219 T1 SMT202000219 T1 SM T202000219T1 SM 20200219 T SM20200219 T SM 20200219T SM T202000219 T SMT202000219 T SM T202000219T SM T202000219 T1 SMT202000219 T1 SM T202000219T1
Authority
SM
San Marino
Prior art keywords
pharmacophore
trail induction
trail
induction
Prior art date
Application number
SM20200219T
Other languages
English (en)
Italian (it)
Inventor
Kim D Janda
Nicholas T Jacob
Jonathan W Lockner
Original Assignee
Scripps Research Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Inst filed Critical Scripps Research Inst
Publication of SMT202000219T1 publication Critical patent/SMT202000219T1/it

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SM20200219T 2014-03-31 2015-03-30 Farmacoforo per l'unduzione di trail SMT202000219T1 (it)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461972689P 2014-03-31 2014-03-31
PCT/US2015/023362 WO2015153468A1 (en) 2014-03-31 2015-03-30 Pharmacophore for trail induction
EP15772254.7A EP3125898B1 (en) 2014-03-31 2015-03-30 Pharmacophore for trail induction

Publications (1)

Publication Number Publication Date
SMT202000219T1 true SMT202000219T1 (it) 2020-05-08

Family

ID=54241169

Family Applications (2)

Application Number Title Priority Date Filing Date
SM20200219T SMT202000219T1 (it) 2014-03-31 2015-03-30 Farmacoforo per l'unduzione di trail
SM20240497T SMT202400497T1 (it) 2014-03-31 2015-03-30 Farmacoforo per induzione di trail

Family Applications After (1)

Application Number Title Priority Date Filing Date
SM20240497T SMT202400497T1 (it) 2014-03-31 2015-03-30 Farmacoforo per induzione di trail

Country Status (20)

Country Link
US (5) US10239877B2 (enExample)
EP (3) EP3125898B1 (enExample)
JP (4) JP6756435B2 (enExample)
KR (2) KR102611067B1 (enExample)
CN (2) CN111499636B (enExample)
AU (5) AU2015241069B2 (enExample)
CA (2) CA3158795A1 (enExample)
CY (1) CY1123093T1 (enExample)
DK (2) DK3125898T3 (enExample)
ES (2) ES2779979T3 (enExample)
FI (1) FI3662910T3 (enExample)
HR (2) HRP20200478T1 (enExample)
HU (2) HUE069651T2 (enExample)
LT (2) LT3125898T (enExample)
PL (2) PL3125898T3 (enExample)
PT (2) PT3125898T (enExample)
RS (2) RS60163B1 (enExample)
SI (2) SI3662910T1 (enExample)
SM (2) SMT202000219T1 (enExample)
WO (1) WO2015153468A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9376437B2 (en) 2013-03-13 2016-06-28 Oncoceutics, Inc 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1H)-one, salts thereof and methods of using the same in combination therapy
PL2968294T3 (pl) 2013-03-13 2019-10-31 Oncoceutics Inc 7-Benzylo-10-(2-metylobenzylo)-2,6,7,8,9,10-heksahydroimidazo[1,2-a]pirydo[4,3-d]pirymidyn-5(3H)-on do zastosowania w leczeniu nowotworu
US9688679B2 (en) 2013-03-13 2017-06-27 Oncoceutics, Inc. 7-benzyl-4-(methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-A]pyrido[3,4-E]pyrimidin-5 (1H)-one, salts thereof and methods of using the same in combination therapy
SMT201900291T1 (it) * 2013-11-15 2019-07-11 Oncoceutics Inc 7-benzil-4-(2-metilbenzil)-2,4,6,7,8,9-esaidriomidazo[1,2-a]pirido[3,4-e]pirimidin-5(1h)-one, suoi sali e metodi d'uso
HUE069651T2 (hu) 2014-03-31 2025-03-28 Scripps Research Inst Farmakofór TRAIL indukcióra
SMT202500087T1 (it) * 2015-01-30 2025-03-12 Oncoceutics Inc Derivati di 7-benzil-4-(2-metilbenzil)-2,4,6,7,8,9-esaidroimidazo[1,2-a]pirido[3,4-e]pirimidin-5(1h)-one, loro sali e loro uso in terapia
CN104860948B (zh) 2015-05-15 2017-09-26 南京盖特医药技术有限公司 咪唑并嘧啶酮类化合物及其制备方法和应用
WO2017132661A2 (en) * 2016-01-29 2017-08-03 Oncoceutics, Inc. G protein-coupled receptor (gpcr) modulation by imipridones
US11091483B2 (en) 2016-08-12 2021-08-17 Madera Therapeutics, LLC Protein kinase regulators
US10172862B2 (en) 2017-01-30 2019-01-08 Oncoceutics, Inc. Imipridones for gliomas
GB2596010B (en) * 2019-02-11 2023-03-01 Madera Therapeutics Llc Use of caseinolytic protease P function as a biomarker of drug response to imipridone-like agents
AU2020228047B2 (en) 2019-02-27 2025-11-20 Madera Therapeutics, LLC Use of caseinolytic protease P function as a biomarker of drug response to imipridone-like agents
BR112023002082A2 (pt) 2020-08-06 2023-05-09 Eoetvoes Lorand Tudomanyegyetem Síntese de derivados de imipridona e sua avaliação para sua atividade anticancerígena
CN115448921B (zh) * 2021-06-08 2023-08-01 四川大学 一类咪唑烷并嘧啶酮化合物及在治疗HsClpP介导的疾病中的用途
CN116751199B (zh) * 2023-06-02 2025-03-18 中国科学院基础医学与肿瘤研究所(筹) 一种线粒体蛋白酶靶向嵌合体、制备方法及用途
EP4684834A1 (de) * 2024-07-26 2026-01-28 BRIU GmbH Kristallformen onkologisch wirksamer imipridone und verfahren zu deren herstellung

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE786028A (fr) * 1971-07-08 1973-01-08 Boehringer Sohn Ingelheim 2,3-dihydro-oxo-imidazo(1,2-a)-pyrimidines, leurs sels d'addition avec des acides et procedes pour les fabriquer
DE2150062A1 (de) 1971-10-07 1973-04-12 Boehringer Sohn Ingelheim Imidazo- eckige klammer auf 1,2-a eckige klammer zu -pyrido- eckige klammer auf 4,3-d eckige klammer zu -pyrimidine, deren saeureadditionssalze und verfahren zu deren herstellung
JPS5374893A (en) 1976-12-15 1978-07-03 Fujitsu Ltd Driving method for semiconductor photosensitive device
JPS6132833U (ja) 1984-07-31 1986-02-27 日信工業株式会社 デイスクブレ−キ装置
EP1517904A4 (en) * 2002-05-23 2007-02-21 Merck & Co Inc INHIBITORS OF MITOTIC KINESINE
PT2303264T (pt) * 2008-06-09 2018-05-14 Allergan Inc Métodos de tratamento de condições mediadas adrenérgicas alfa utilizando derivados de imidazolina
CA2795952A1 (en) * 2010-04-16 2011-10-20 Curis, Inc. Treatment of cancers having k-ras mutations
WO2012078448A1 (en) * 2010-12-06 2012-06-14 Schering Corporation Tricyclic heterocycles useful as dipeptidyl peptidase-iv inhibitors
TWI658047B (zh) * 2011-03-15 2019-05-01 吉斯藥品公司 異唑啶衍生物
WO2012138789A2 (en) * 2011-04-04 2012-10-11 Netherlands Cancer Institute Methods and compositions for predicting resistance to anticancer treatment
RS67757B1 (sr) 2011-04-29 2026-03-31 Penn State Res Found Indukcija malim molekulom trail gena u normalnim i tumorskim ćelijama kao antikancerska terapija
WO2015073072A1 (en) * 2013-11-15 2015-05-21 Oncoceutics, Inc. 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1h)-one
US9376437B2 (en) * 2013-03-13 2016-06-28 Oncoceutics, Inc 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1H)-one, salts thereof and methods of using the same in combination therapy
US9688679B2 (en) 2013-03-13 2017-06-27 Oncoceutics, Inc. 7-benzyl-4-(methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-A]pyrido[3,4-E]pyrimidin-5 (1H)-one, salts thereof and methods of using the same in combination therapy
PL2968294T3 (pl) * 2013-03-13 2019-10-31 Oncoceutics Inc 7-Benzylo-10-(2-metylobenzylo)-2,6,7,8,9,10-heksahydroimidazo[1,2-a]pirydo[4,3-d]pirymidyn-5(3H)-on do zastosowania w leczeniu nowotworu
US9181237B2 (en) * 2013-10-04 2015-11-10 Mallinckrodt Llc Substituted berbines and their synthesis
HUE069651T2 (hu) 2014-03-31 2025-03-28 Scripps Research Inst Farmakofór TRAIL indukcióra

Also Published As

Publication number Publication date
EP4470617A2 (en) 2024-12-04
PL3125898T3 (pl) 2020-11-16
ES2779979T3 (es) 2020-08-21
EP4470617A3 (en) 2025-02-26
KR102611067B1 (ko) 2023-12-06
RS60163B1 (sr) 2020-05-29
US10239877B2 (en) 2019-03-26
EP3125898A4 (en) 2017-08-16
PT3125898T (pt) 2020-04-01
PT3662910T (pt) 2024-11-27
KR20220163533A (ko) 2022-12-09
LT3125898T (lt) 2020-04-10
HUE049013T2 (hu) 2020-08-28
AU2015241069B2 (en) 2020-10-15
US10633385B2 (en) 2020-04-28
AU2015241069A1 (en) 2016-10-20
CA2944452C (en) 2022-07-19
JP6756435B2 (ja) 2020-09-16
CN106456643B (zh) 2020-04-17
PL3662910T3 (pl) 2025-08-11
CA3158795A1 (en) 2015-10-08
DK3662910T3 (en) 2024-11-04
US12630550B2 (en) 2026-05-19
AU2024204977B2 (en) 2026-04-16
CN106456643A (zh) 2017-02-22
JP6873201B2 (ja) 2021-05-19
ES2999685T3 (en) 2025-02-26
CN111499636A (zh) 2020-08-07
SMT202400497T1 (it) 2025-01-14
RS66254B1 (sr) 2024-12-31
CY1123093T1 (el) 2021-10-29
US20220002300A1 (en) 2022-01-06
KR20160138513A (ko) 2016-12-05
US20200283440A1 (en) 2020-09-10
US20170107221A1 (en) 2017-04-20
HUE069651T2 (hu) 2025-03-28
SI3125898T1 (sl) 2020-07-31
JP2020002170A (ja) 2020-01-09
JP2017511321A (ja) 2017-04-20
US20190284188A1 (en) 2019-09-19
EP3662910A1 (en) 2020-06-10
JP2021119157A (ja) 2021-08-12
HRP20200478T1 (hr) 2020-07-24
JP2023022184A (ja) 2023-02-14
AU2026206080A1 (en) 2026-07-30
AU2024204977A1 (en) 2024-08-08
US11891392B2 (en) 2024-02-06
DK3125898T3 (da) 2020-03-30
CN111499636B (zh) 2023-01-13
EP3662910B1 (en) 2024-09-18
CA2944452A1 (en) 2015-10-08
EP3125898A1 (en) 2017-02-08
US20240190877A1 (en) 2024-06-13
JP7688245B2 (ja) 2025-06-04
LT3662910T (lt) 2024-12-27
JP7186256B2 (ja) 2022-12-08
WO2015153468A1 (en) 2015-10-08
KR102473930B1 (ko) 2022-12-05
EP3125898B1 (en) 2019-12-25
SI3662910T1 (sl) 2025-05-30
AU2022283729A1 (en) 2023-02-02
HRP20241680T1 (hr) 2025-02-28
AU2020286314A1 (en) 2021-01-21
FI3662910T3 (fi) 2024-10-31

Similar Documents

Publication Publication Date Title
GB2531928B (en) Image-stitching for dimensioning
DK3662910T3 (en) Pharmacophore for trail induction
GB201817189D0 (en) Image-stitching for dimensioning
AP2017009836A0 (en) Aminopyridyloxypyrazole compounds
PL3097397T3 (pl) Szynowy system pomiarowy
GB201411418D0 (en) Compounds
GB201415573D0 (en) Compounds
GB201410430D0 (en) Compounds
GB201416186D0 (en) Compounds
GB201402431D0 (en) Compounds
GB201406591D0 (en) Compounds
GB201406956D0 (en) Compounds
GB201404987D0 (en) Compounds
GB2524311B (en) Centraliser
GB201412660D0 (en) Compounds
AP2017009778A0 (en) Azetidinyloxyphenylpyrrolidine compounds
GB201407695D0 (en) Compounds
GB201403438D0 (en) Polymorphs
GB2525001B (en) Centraliser
GB201405361D0 (en) Compounds
IL233408A0 (en) New Skin - Perineal
GB201416116D0 (en) Compounds
GB201415570D0 (en) Compounds
GB201415571D0 (en) Compounds
AP2014007674A0 (en) Chengie-advanced claypot de-fluoridation technology